Keynote Lecture 11 “Pharmacokinetic considerations for inhaled natural product mixtures to treat lung infections”

Acute respiratory infections (ARIs) caused by viruses and/or bacteria are responsible for the most frequently occurring contagious diseases worldwide and the most common cause of death from communicable diseases. The high mortality rates associated with viral and bacterial ARIs highlight the need for the accelerated identification and assessment of new effective anti-ARI therapeutics. Poor oral bioavailability of many new classes of antibiotics and anti-infectives, especially those derived from natural product sources, can slow or hinder the development of promising treatment options. Inhalation administration of antibiotics/anti-infectives for the treatment of local lung infections may offer a sensible alternative to oral administration. However, it is not widely recognized that the local pharmacokinetics of drug compounds in the lung can be highly dependent on drug compound structure and formulation. For example, compound solubility and permeability will play an important role in determining whether inhalation administration is a feasible option and whether special formulation approaches, such as liposomal encapsulation, may be advantageous.

This presentation will:

1. provide an overview on pharmacokinetics of a wide variety of antibiotic compound classes in the lung

2. discuss how target product profiles and pre-formulation studies may streamline early product development

3. discuss how this knowledge may be extended towards the investigation of inhaled natural product mixtures

4. introduce the concept of pharmacokinetic synergy for natural product mixtures

5. demonstrate the effects of drug formulation strategies for controlling lung pharmacokinetics of inhaled drugs

 

MissingLinkText

Conflict of Interest

The author declares no conflict of interest.

Publication History

Article published online:
16 November 2023